Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Once-Weekly Eloralintide Added to Weekly Incretin Therapy in Adults With Obesity or Overweight
jRCT2031250803Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2026
- Modality
- Peptides
01
Overview
Phase 3, randomised, double-blind trial of eloralintide in obesity, Overweight, type 2 diabetes mellitus (T2DM) and 4 more (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percent Change from Baseline in Body Weight. Started Apr 2026; status: recruiting.
02
Drugs
eloralintide
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on jRCT2031250803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250803.